230,101 Shares in TriSalus Life Sciences, Inc. $TLSI Purchased by Perkins Capital Management Inc.

Perkins Capital Management Inc. purchased a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 230,101 shares of the company’s stock, valued at approximately $920,000.

A number of other large investors have also recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in shares of TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after acquiring an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in TriSalus Life Sciences in the second quarter valued at $47,000. Invesco Ltd. purchased a new position in TriSalus Life Sciences during the 4th quarter valued at $72,000. Abel Hall LLC purchased a new position in TriSalus Life Sciences during the 4th quarter valued at $73,000. Finally, HighMark Wealth Management LLC bought a new position in TriSalus Life Sciences in the 4th quarter worth $75,000. 2.58% of the stock is currently owned by institutional investors.

Insider Transactions at TriSalus Life Sciences

In other TriSalus Life Sciences news, Director Michael P. Stansky purchased 200,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average cost of $2.50 per share, with a total value of $500,000.00. Following the transaction, the director directly owned 399,698 shares in the company, valued at approximately $999,245. The trade was a 100.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Mats Wahlstrom purchased 60,000 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average cost of $2.53 per share, with a total value of $151,800.00. Following the completion of the transaction, the director owned 147,555 shares in the company, valued at $373,314.15. This trade represents a 68.53% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 719,682 shares of company stock valued at $1,804,176 in the last three months. 16.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently commented on TLSI. Canaccord Genuity Group dropped their target price on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings lowered shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Finally, Lake Street Capital cut their price objective on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $7.50.

TriSalus Life Sciences Price Performance

TLSI opened at $4.55 on Wednesday. The company has a current ratio of 5.78, a quick ratio of 5.46 and a debt-to-equity ratio of 2.58. The company has a market cap of $279.46 million, a price-to-earnings ratio of -3.23 and a beta of 0.48. The stock has a fifty day simple moving average of $3.87 and a two-hundred day simple moving average of $4.74. TriSalus Life Sciences, Inc. has a 12-month low of $2.20 and a 12-month high of $7.95.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.